E
Edgewood Oncology
We look forward to further developing this compound using a precision medicine approach in patient populations who lack effective treatment options
About Edgewood Oncology
Edgewood Oncology is a clinical-stage biotechnology company focused on advancing BTX A51, a novel small molecule, multi-kinase inhibitor. The company targets hematologic malignancies and genetically defined solid tumors, including GATA3 mutant breast cancer. Edgewood Oncology operates in the precision medicine market, aiming to provide effective treatment options for patients with significant unmet medical needs. The business model revolves around developing and commercializing BTX A51 through clinical trials and partnerships. Revenue is generated through funding rounds, such as the recent $20 million Series A financing, and future commercialization of their therapies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2024 | $20M | $80M | Alta Partners | ↗ |
| SPINOUT✓Other financing | Jan 2023 | $0 | — | Yissum Research Development · The Hebrew University of Jerusalem | — |
Growth signals
Latest recorded traffic for Edgewood Oncology is 1.5K monthly website visits, up 158.6% over the last three months. Edgewood Oncology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Edgewood Oncology in the Brookline ecosystem
The Edgewood Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Alta Partners
Other known investors2 additional known investors
The Hebrew University of Jerusalem
Yissum Research Development
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Edgewood Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Edgewood Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









